 | | Vol. 23.30 – 29 August, 2022 |
| |
|
|
| Ablation of RASA2 in multiple preclinical models of T cell receptor and CAR T cell therapies prolonged survival in mice xenografted with either liquid or solid tumors.
[Nature] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers assessed whether tumor immune contexture influenced clinical outcomes after axicabtagene ciloleucel. They evaluated the tumor microenvironment of 135 pre-treatment and post-treatment tumor biopsies taken from 51 patients in the ZUMA-1 Phase II trial.
[Nature Medicine] |
|
|
|
| The authors tested myxoma virus (MYXV)-infected tumor-specific T cells expressing CAR or T cell receptor (TCR), which systemically delivered MYXV into solid tumors to overcome primary resistance.
[Cancer Cell] |
|
|
|
| Scientists engineered hybrid spheroids of mesenchymal stem cells with rapamycin-releasing poly(lactic-co-glycolic acid) microparticles to prevent immune rejection of islet xenografts in diabetic C57BL/6 mice.
[Science Advances] |
|
|
|
| In a mice volumetric muscle loss model, injection of a microcryogel loaded with muscle-derived stem cells into the injury site significantly improved the generation of new muscle fibers and blood vessels and anti-inflammatory properties.
[Acta Biomaterialia] |
|
|
|
| The authors suggested that the dopamine-methacrylated hyaluronic acid hydrogel firmly adhered to the skin wound defect and promoted cell proliferation in vitro and skin defect regeneration in vivo.
[Cell Death & Disease] |
|
|
|
| Scientists evaluated long-term survival and late effects in 137 patients affected by thalassemia major who received an allogeneic hematopoietic cell transplantation.
[Bone Marrow Transplantation] |
|
|
|
| Investigators showed that the sequential use of different T cell redirection therapies was possible and could lead to deep and durable responses following relapse after bispecific antibody therapy in relapsed/refractory multiple myeloma.
[Blood Advances] |
|
|
|
| Definitive proof of CARHI T cells improved antitumor efficacy was demonstrated in a human Hodgkin’s lymphoma xenograft mouse model, where CAR30-TSCM-LIKE enriched products with high intensity of CAR expression achieved superior tumor control in vivo than those with a low intensity of CAR expression.
[Cancer Gene Therapy] |
|
|
|
| Researchers retrospectively compared the outcomes of 52 peripheral T cell lymphoma patients treated with lomustine, etoposide, cytarabine, and cyclophosphamide (CEAC), carmustine, etoposide, cytarabine, and melphalan (BEAM), and idarubicin, etoposide, cytarabine and cyclophosphamide (IEAC) regimens.
[Scientific Reports] |
|
|
|
| All patients enrolled in the VITAL trial of maintenance gemogenovatucel-T vs. placebo as front-line therapy with homologous recombination proficient stage IIIB-IV newly diagnosed ovarian cancer underwent NanoString gene expression analysis.
[Communications Medicine] |
|
|
|
| The authors evaluated the effect of immune checkpoint inhibitors blocking programmed cell death protein ligand 1 and cytotoxic T lymphocyte-associated antigen 4 on the ovary using tumor-bearing and tumor-free mouse models.
[Nature Cancer] |
|
|
|
|
| Investigators identify the challenges impeding the translation of strategies and technologies for cell-based cartilage repair, such as the disconnect between university funding and regulatory requirements.
[Science Translational Medicine] |
|
|
|
| The authors summarize the progress of immunotherapy for the treatment of HCC including immune checkpoint inhibitors, liver cancer vaccines, and cellular therapies.
[Clinical and Experimental Medicine] |
|
|
|
| The best source of mesenchymal stem cells seems to be the umbilical cord due to the easiness of extraction, the noninvasive method of collection, their higher expansion ability, and more powerful immune-modulating properties compared to other locations in the body.
[Regenerative Therapy] |
|
|
|
|
| Porton Advanced Solutions announced a strategic cooperation with Suzhou Royaltech Med Co., Ltd that will promote the establishment of microbial vectors used for gene therapy and mRNA drug platform technology, and accelerate the R&D process of bioinnovative drugs.
[Porton Advanced Solutions (Cision US, Inc.)] |
|
|
|
| Regen BioPharma, Inc. announced the development of a novel immunotherapy for treatment of solid tumors. The current approach developed by the company involves initial treatment of the tumor microenvironment with cells of the innate immune system called CAR-M and CAR-NK cells.
[Regen BioPharma, Inc. (Cision US, Inc.)] |
|
|
|
| Longeveron, Inc. announced that the European Patent Office has issued a notice of its intent to grant the company a patent related to methods to treat endothelial dysfunction and monitor the efficacy of allogeneic mesenchymal cell therapies, also known as medicinal signaling cells.
[Longeveron, Inc.] |
|
|
|
|
| November 16 – 18, 2022
Melbourne, Victoria, Australia |
|
|
|
|
|
| | University of Michigan – Ann Arbor, Michigan, United States |
|
|
|
| | St. Jude Children’s Research Hospital – Memphis, Tennessee, United States |
|
|
|
| | Darmstadt University of Technology – Darmstadt, Germany |
|
|
|
| | Dalhousie University – Halifax, Nova Scotia, Canada |
|
|
|
| | STEMCELL Technologies, Inc. – Vancouver, British Columbia, Canada |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
